Kazia Therapeutics (KZIA) AI Stock Analysis

• Market Cap: $12.80M
• Dividend Yield: N/A
• Average Volume (3M): 209.48K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.12
• Revenue Growth: -98.25%
• EPS Growth: 63.05%
• Country: US
• Employees: 9
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 1,670,578
• 10 Day Avg. Volume: 60,839
• 30 Day Avg. Volume: 209,481
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $19.00
• Price Target Upside: 82.17% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 31 Underperform
• Price Target: ―

Kazia Therapeutics has a low overall stock score due to significant financial instability marked by declining revenues, negative equity, and cash flow issues. Technical indicators suggest bearish momentum, and poor valuation metrics reflect the company's unprofitability. The absence of dividends and positive earnings call or corporate events data further emphasize the company's challenges.

Positive Factors

Innovative Oncology Focus

Kazia's focus on developing novel cancer therapeutics, particularly for aggressive forms like glioblastoma, positions it well in a high-demand market, potentially leading to significant breakthroughs and partnerships.

Strategic Partnerships

Strategic partnerships enhance Kazia's research capabilities and provide funding, which is vital for advancing clinical trials and increasing the likelihood of successful drug commercialization.

Pipeline Potential

Paxalisib's development for glioblastoma addresses unmet medical needs, offering potential for significant impact in oncology treatment and future revenue streams upon successful trials and approval.

Negative Factors

Financial Instability

The company's financial instability, marked by negative equity and cash flow issues, threatens its operational sustainability and ability to fund ongoing research without external investment.

Negative Cash Flow

Negative cash flow indicates Kazia is not generating enough cash from operations, which could hinder its ability to cover expenses and invest in R&D, necessitating reliance on external financing.

Declining Revenue

Declining revenue reflects challenges in commercializing products and achieving growth, which could impact long-term viability and investor confidence if not addressed.

Kazia Therapeutics Business Overview & Revenue Model

Company Description

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

How the Company Makes Money

Kazia Therapeutics primarily generates revenue through the development and potential commercialization of its drug candidates. The company seeks to advance its therapies through clinical trials and, upon successful results and regulatory approval, aims to license its drugs to larger pharmaceutical companies or bring them to market directly. Key revenue streams include milestone payments, royalties from licensing agreements, and potential sales revenue of approved drugs. Partnerships with research institutions and pharmaceutical companies also play a crucial role in funding and advancing their drug development programs.

Kazia Therapeutics Financial Statement Overview

Summary

Kazia Therapeutics is facing financial challenges with declining revenues, persistent losses, and negative equity. The company struggles with cash flow generation and financial stability, which could affect its ability to sustain operations without significant changes or external funding.

Income Statement

Kazia Therapeutics has shown declining revenue over the years with a significant drop in total revenue in the most recent period. The company is experiencing a negative net profit margin, indicating it is not profitable. Moreover, both EBIT and EBITDA margins are negative, highlighting operational inefficiencies and challenges in controlling costs.

Balance Sheet

The company's financial structure is concerning, with negative stockholders' equity in the latest period, indicating liabilities exceed assets. The debt-to-equity ratio is not applicable due to negative equity, which poses a financial risk. Moreover, the equity ratio is negative, underscoring the financial instability and leverage issues.

Cash Flow

There is a negative operating cash flow and free cash flow, indicating that the company is not generating sufficient cash from its operations. The free cash flow growth rate is negative, suggesting worsening liquidity and inability to cover expenses without external financing.

Breakdown	TTM	Dec 2025	Dec 2025	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	2.50M	―	42.00K	2.31M	555.00	10.00K
Gross Profit	2.50M	―	42.00K	2.31M	555.00	10.00K
EBITDA	-27.08M	―	-13.28M	-26.59M	-22.28M	-23.52M
Net Income	-28.41M	―	-20.70M	-26.78M	-20.47M	-25.01M
Balance Sheet
Total Assets	17.91M	―	6.06M	21.59M	28.08M	35.89M
Cash, Cash Equivalents and Short-Term Investments	3.06M	―	4.34M	1.66M	5.24M	7.36M
Total Debt	140.74K	―	396.00K	634.00K	1.80M	1.84M
Total Liabilities	21.72M	―	14.36M	31.60M	16.03M	17.61M
Stockholders Equity	-3.81M	―	-8.30M	-10.02M	12.05M	18.27M
Cash Flow
Free Cash Flow	-7.46M	―	-13.28M	-9.58M	-15.16M	-22.76M
Operating Cash Flow	-7.46M	―	-13.28M	-9.58M	-15.16M	-22.76M
Investing Cash Flow	0.00	―	0.00	0.00	0.00	-2.37M
Financing Cash Flow	5.49M	―	15.98M	5.99M	12.97M	3.73M

Kazia Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 10.43
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KZIA, the sentiment is Neutral. The current price of 10.43 is below the 20-day moving average (MA) of 10.60, above the 50-day MA of 8.58, and above the 200-day MA of 6.83, indicating a neutral trend. The MACD of 1.47 indicates Negative momentum. The RSI at 49.29 is Neutral, neither overbought nor oversold. The STOCH value of 45.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KZIA.

Kazia Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MRKR	44 Neutral	$22.01M	―	-110.67%	―	-12.99%	-13.67%
PHIO	42 Neutral	$14.10M	-0.59	-107.58%	―	―	83.95%
XTLB	39 Underperform	$7.52M	―	―	―	―	65.45%
KZIA	31 Underperform	$12.80M	-0.26	―	―	-98.25%	63.05%
GLTO	29 Underperform	$7.87M	-0.44	-114.81%	―	―	37.42%
RNAZ	27 Underperform	$7.92M	-0.02	-1763.01%	―	―	96.75%